International Isotopes Inc. Announces Year End Financial Results
Company Shows a 19% Increase In Total Revenue To
Total Revenue. Total revenue in 2008 was
Business Segment Area 2008 2007 Percent Change Nuclear Medicine Products $1,864,099 $1,819,049 2% Radiochemical Products $1,379,906 $1,062,477 30% Cobalt Products $1,616,020 $1,064,727 52% Radiological Services $634,201 $590,160 7% Transportation $108,217 $154,175 (30%) Total Revenue $5,602,443 $4,690,588 19%
Cost of Revenue and Gross Profit. Cost of revenue for 2008, was
Operating Costs and Expenses. Total operating costs and expenses for 2008, were
Net Loss. Net Loss was
International Isotopes Inc. Year Ended Dec. 31 2008 2007 Change $'s Change % Sales of Products $5,602,443 $4,690,588 $911,855 19% Gross Profit $2,722,604 $2,029,807 $692,797 34% Total Operating Expense $4,827,985 $3,645,549 $1,182,436 32% Operating Loss Before Other Expense ($2,105,381) ($1,615,742) $489,639 (30%) Other Expense ($61,586) (103,313) $41,727 40% Net Loss ($2,166,967) ($1,719,055) ($447,912) (26%) Net (Loss) Per Common Share ($0.01) ($0.01) Weighted Ave. Sh. Outstanding 276,486,713 238,939,638
About International Isotopes Inc.
International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients.
International Isotopes Inc. Safe Harbor Statement
Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statement with respect to improving our financial performance; increasing our revenue; designing and constructing a depleted uranium de-conversion and fluorine extraction process facility; and beginning commercial sales of fluorine products. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes, Inc. to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in International Isotopes, Inc.’s filings with the Securities and Exchange Commission at www.sec.gov, including our annual report on Form 10-K for the year ending
For More Information, Contact: Steve Laflin, President and CEO (208) 524-5300
SOURCE International Isotopes Inc.